Apimeds Pharmaceuticals US, Inc. (APUS) - Total Liabilities
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has total liabilities worth $14.70 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Apimeds Pharmaceuticals US, Inc. to see how much of total assets are deployed in long-term investments.
Apimeds Pharmaceuticals US, Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see APUS current and non-current assets.
Apimeds Pharmaceuticals US, Inc. Competitors by Total Liabilities
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
USA | $7.49 Million |
|
Serabi Gold PLC
LSE:SRB
|
UK | GBX29.61 Million |
|
PolyPlank publ AB
ST:POLY
|
Sweden | Skr21.55 Million |
|
Ostrom Climate Solutions Inc
V:COO
|
Canada | CA$13.69 Million |
|
Scout Security Ltd
AU:SCT
|
Australia | AU$11.61 Million |
|
John Wood Group PLC
LSE:WG
|
UK | GBX3.24 Billion |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
Poland | zł8.32 Million |
|
CL8 Holdings Ltd
AU:CL8
|
Australia | AU$13.01 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Apimeds Pharmaceuticals US, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Apimeds Pharmaceuticals US, Inc. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apimeds Pharmaceuticals US, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apimeds Pharmaceuticals US, Inc. (2021–2025)
The table below shows the annual total liabilities of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.84 Million | +690.26% |
| 2024-12-31 | $1.37 Million | +251.40% |
| 2023-12-31 | $390.20K | -45.79% |
| 2022-12-31 | $719.78K | +75.28% |
| 2021-12-31 | $410.65K | -- |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.